NGNE (Neurogene) Net Margin %: 0.00% (As of Mar. 2026)


NGNE Neurogene Inc NGNE
12 GF Score
Price $32.05
! 4 Warning Signs
View Full Analysis

What is Neurogene Net Margin %?

Neurogene NGNE +5.26% 12 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates NGNE with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Neurogene ranks worse than 105820% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Neurogene's Net Income for the three months ended in Mar. 2026 was $-30.93 Mil. Neurogene's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Neurogene's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Neurogene's Net Margin % or its related term are showing as below:


NGNE's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Neurogene  (NAS:NGNE) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Neurogene Net Margin % Related Terms

Neurogene Net Margin % Historical Data

* Premium members only.

The historical data trend for Neurogene's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurogene Net Margin % Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
0.00 0.00 0.00 -8,123.68 0.00

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NGNE vs SGMT, IPSC, UPB: Net Margin % Comparison

For the Biotechnology subindustry, Neurogene's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurogene Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurogene's Net Margin % distribution charts can be found below:

* The bar in red indicates where Neurogene's Net Margin % falls into.


NGNE
12GF Score
Neurogene Inc NGNE
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurogene Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Neurogene's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-90.351/0
= %

Neurogene's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-30.934/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Neurogene (NGNE) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Neurogene and its competitors. According to the industry distribution chart, Neurogene ranks #999999 out of 945 companies in the Biotechnology industry.
Is Neurogene's Net Margin % too high?
Neurogene's current Net Margin % is 0.00%. Based on the distribution chart, Neurogene ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Neurogene has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Neurogene's Net Margin % compare to SGMT and IPSC?
According to the Biotechnology industry distribution chart, Neurogene ranks #999999 out of 945 companies for Net Margin %. This places Neurogene in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Neurogene and its competitors. Neurogene's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurogene stock overvalued right now?
Neurogene (NGNE) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Neurogene's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Neurogene (NGNE), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurogene Business Description

Other Exchanges UU8:Germany
Address 535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
12GF Score

Get the complete analysis for NGNE

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.05
Price